Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Faeth Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 31 | 28 | −3 |
| Shares | 2.88M | 2.64M | −243.6K (−8.4%) |
| Value | $4.47M | $3.93M | −$533.3K (−11.9%) |
New holders (4)
Institutions that held Faeth Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Western Standard LLC | 46,117 | $68.7K | 0.06% |
| Virtu Financial LLC | 26,060 | $39.0K | 0.01% |
| Deuterium Capital Management, LLC | 11,900 | $17.7K | 0.05% |
| Fiduciary Alliance LLC | 50 | $75 | 0.00% |
Sold out (7)
Institutions that held Faeth Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 683,529 | $1.06M |
| HighTower Advisors, LLC | 50,229 | $78.0K |
| Qube Research & Technologies Ltd | 16,711 | $26.0K |
| Goldman Sachs Group Inc | 10,446 | $16.0K |
| Citigroup Inc | 361 | $1.00K |
| BNP Paribas Arbitrage, SA | 603 | $935 |
| China Universal Asset Management Co., Ltd. | 288 | $0 |